Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
Case ReportCase Report

Atypical Diffusion-Restricted Lesion in 5-Fluorouracil Encephalopathy

W.-W. Lee, J.-S. Kim, K.R. Son and H.-M. Kwon
American Journal of Neuroradiology August 2012, 33 (7) E102-E103; DOI: https://doi.org/10.3174/ajnr.A2781
W.-W. Lee
aFrom the Department of Neurology (W.-W.L., J.-S.K., H.-M.K.), Seoul Metropolitan Government-Seoul National University Boramae Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.-S. Kim
aFrom the Department of Neurology (W.-W.L., J.-S.K., H.-M.K.), Seoul Metropolitan Government-Seoul National University Boramae Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K.R. Son
bDepartment of Diagnostic Radiology (K.R.S.), Korea University College of Medicine, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.-M. Kwon
aFrom the Department of Neurology (W.-W.L., J.-S.K., H.-M.K.), Seoul Metropolitan Government-Seoul National University Boramae Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

SUMMARY: Central nervous system toxicity of 5-FU could show various manifestations, such as decreased alertness, disorientation, and agitation. It is generally accepted that lesions of 5-FU encephalopathy are mainly in the deep cerebral white matter and corpus callosum on MR imaging. Here we describe a case of 5-FU encephalopathy in gastric cancer with an atypical reversible diffusion-restricted lesion on MR imaging, showing bilateral basal ganglia, thalami, and parasagittal frontal cortex involvement on diffusion and T2-weighted imaging.

ABBREVIATIONS:

BUN
blood urea nitrogen
CRF
chronic renal failure
DPD
dihydropyrimidine dehydrogenase
5-FU
5-fluorouracil
PT/INR
prothrombin time/international normalized ratio

5-FU is a chemotherapeutic agent that is frequently used to treat breast, head and neck, colon, and stomach cancer. Among the neurotoxic effects of 5-FU, the cerebellar syndrome is the most frequent, whereas encephalopathy is uncommon and mostly reversible.1 Various symptoms of 5-FU encephalopathy include decreased alertness, disorientation, and agitation. It is generally accepted that 5-FU encephalopathy lesions seen on MR imaging are located mainly in deep white matter and the corpus callosum.2,3 Here, we describe a case of 5-FU encephalopathy with atypical diffusion-restricted lesions.

Case Report

A 49-year-old man, who had undergone total gastrectomy for gastric cancer 3 months previously, was admitted for chemotherapy to the oncology division. He had a history of hypertension and CRF. He was taking ferrous sulfate, aspirin, furosemide, multivitamins, calcium carbonate, and erythropoietin. The patient had undergone hemodialysis 3 times weekly on a regular basis. He was not a heavy alcohol drinker, and there was no additional significant medical, social, or family history. On initial examination, the patient did not show any abnormal neurologic symptoms or signs. Routine laboratory data indicated anemia and CRF. BUN and creatinine levels fluctuated according to the hemodialysis schedule (36∼94 mg/dL and 4.7∼6.9 mg/dL, respectively).

The patient was administered intravenous 5-FU (410 mg daily) and had no chemotherapy-related symptoms except nausea and vomiting. On the fourth day of the first cycle of 5-FU chemotherapy, he became semicomatose after a nap. He showed intermittent tremulous movement of all extremities and roving eye movements. All brain stem reflexes were intact. Brain MR imaging revealed diffusion restriction in the bilateral basal ganglia, thalami, and parasagittal frontal cortex. High-signal-intensity lesions were detected in the same locations on FLAIR imaging (Fig 1A). His serum ammonia level was high (265 μg/dL; normal range, 0–75 μg/dL), and the PT/INR was prolonged to 1.85. His serum thiamine level was within normal limits (115.5 nmol/L), and BUN and creatinine levels were 50 mg/dL and 4.7 mg/dL, respectively. Other laboratory findings, including vitamin B1 and liver function, were unremarkable. An electroencephalogram showed continuous irregular mixed slowing without any epileptiform discharges.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Initial and follow-up brain MR images. Brain MR imaging shows high signal intensities in the bilateral basal ganglia, thalami, and parasagittal frontal cortex at symptom onset (A); improved status after 1 week (B); and no remarkable abnormalities after 3 months (C). There are axial diffusion-weighted images in the left column, an axial apparent diffusion coefficient map in the middle column, and axial FLAIR in the right column.

With cessation of 5-FU, he gradually improved. On the third day after symptom onset, he could obey simple commands, though he was irritable. Follow-up levels of PT/INR and ammonia were normal. After 1 week, he had recovered, and brain MR imaging showed marked improvement (Fig 1B). After 3 months, the abnormal lesions had disappeared on diffusion-weighted and FLAIR imaging (Fig 1C).

Discussion

5-FU encephalopathy usually develops within 7 days from the beginning of the chemotherapy cycle. After 5-FU is discontinued, most patients improve within a few days.3 Lesions of 5-FU encephalopathy are most commonly seen in the deep white matter and corpus callosum.2,3 This present case had clinical characteristics similar to those in previous reports. However, the MR imaging findings disclosed high signal intensities in unusual locations; diffusion- and T2-weighted-images showed involvement of the bilateral basal ganglia and thalami. Although some studies have reported that symmetric lesions of deep gray matter nuclei are also seen in uremic encephalopathy,4 our case showed the following differences: 1) our patient had undergone regular hemodialysis; 2) his serum BUN and creatinine levels remained unchanged with respect to initial data; and 3) the period from symptom onset to recovery was brief.

The disease mechanism of 5-FU encephalopathy is unclear. The toxicity of 5-FU is strongly influenced by the dosage used and the rate and duration of drug administration. Our patient received a small dose according to routine usage. Another possible cause of 5-FU toxicity is a deficit of DPD. More than 80% of administered 5-FU is eliminated by DPD, which suggests that enzyme deficiency would result in highly toxic effects such as severe mucositis, myelosuppression/neutropenia, and severe diarrhea.5 DPD deficiency in our patient is unlikely, given that he did not manifest any of the other severe toxic effects.

Hyperammonemic encephalopathy has also been reported to be a significant cause of neurologic deterioration after chemotherapy.6 The serum ammonia level and PT/INR of our patient were initially increased and became normalized during 3 days, as the patient improved. The association between hyperammonemia and 5-FU encephalopathy may be a clue in determining the mechanism involved.7 We postulate that transient hepatic dysfunction might play an important role in the pathogenesis of reversible 5-FU encephalopathy.

In conclusion, we have reported a case of 5-FU encephalopathy with manifestations of hyperammonemia, prolonged PT/INR, and unique brain MR imaging findings. Additional research is needed to clarify the pathophysiologic mechanism for 5-FU encephalopathy.

References

  1. 1.↵
    1. Sioka C,
    2. Kyritsis AP
    . Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009;63:761–67
    CrossRefPubMed
  2. 2.↵
    1. Lucato LT,
    2. McKinney AM,
    3. Short J,
    4. et al
    . Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity. Australas Radiol 2006;50:364–68
    CrossRefPubMed
  3. 3.↵
    1. Videnovic A,
    2. Semenov I,
    3. Chua-Adajar R,
    4. et al
    . Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology 2005;65:1792–94, discussion 1685. Epub 2005 Oct 19
    Abstract/FREE Full Text
  4. 4.↵
    1. Okada J,
    2. Yoshikawa K,
    3. Matsuo H,
    4. et al
    . Reversible MRI and CT findings in uremic encephalopathy. Neuroradiology 1991;33:524–26
    CrossRefPubMed
  5. 5.↵
    1. van Kuilenburg AB
    . Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939–50
    CrossRefPubMed
  6. 6.↵
    1. Brusilow SW
    . Hyperammonemic encephalopathy. Medicine (Baltimore) 2002;81:240–49
    CrossRefPubMed
  7. 7.↵
    1. Chue AL,
    2. Fernando IN,
    3. Hussain SA,
    4. et al
    . Chemotherapy related encephalopathy in a patient with stage IV cervical carcinoma treated with cisplatin and 5-fluorouracil: a case report. Cases J 2009;2:8526
    CrossRefPubMed
  • Received June 2, 2011.
  • Accepted after revision June 7, 2011.
  • © 2012 by American Journal of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 33 (7)
American Journal of Neuroradiology
Vol. 33, Issue 7
1 Aug 2012
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Atypical Diffusion-Restricted Lesion in 5-Fluorouracil Encephalopathy
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Atypical Diffusion-Restricted Lesion in 5-Fluorouracil Encephalopathy
W.-W. Lee, J.-S. Kim, K.R. Son, H.-M. Kwon
American Journal of Neuroradiology Aug 2012, 33 (7) E102-E103; DOI: 10.3174/ajnr.A2781

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Atypical Diffusion-Restricted Lesion in 5-Fluorouracil Encephalopathy
W.-W. Lee, J.-S. Kim, K.R. Son, H.-M. Kwon
American Journal of Neuroradiology Aug 2012, 33 (7) E102-E103; DOI: 10.3174/ajnr.A2781
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • Case Report
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • 5-Fluorouracil-induced encephalopathy
  • 5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Dural Infantile Hemangioma Masquerading as a Skull Vault Lesion
  • Multimodal Imaging of Spike Propagation: A Technical Case Report
Show more Case Report

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2021 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2022 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire